<br>        Inclusion criteria:<br><br>          -  Healthy male or female subjects according to the investigator's assessment, based on a<br>             complete medical history including a physical examination, vital signs (BP, PR),<br>             12-lead ECG, and clinical laboratory tests<br><br>          -  Age of 18 to 50 years (incl.)<br><br>          -  BMI of 18.5 to 29.9 kg/m2 (incl.)<br><br>          -  Signed and dated written informed consent prior to admission to the study in<br>             accordance with GCP and local legislation<br><br>          -  Male or female subjects who meet any of the following criteria starting from screening<br>             until 30 days after trial completion regarding adequate contraception:<br><br>               -  Non-hormonal intra-uterine device in combination with condom<br><br>               -  Sexually abstinent<br><br>               -  Surgically sterilised (including hysterectomy)<br><br>               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)<br><br>               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in<br>                  questionable cases a blood sample with simultaneous levels of FSH above 40 U/L<br>                  and estradiol below 30 ng/L is confirmatory)<br><br>        Exclusion criteria:<br><br>          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from<br>             normal and judged as clinically relevant by the investigator<br><br>          -  Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,<br>             diastolic blood pressure outside the range of 60 to 90 mmHg, or pulse rate outside the<br>             range of 50 to 85 bpm<br><br>          -  Any laboratory value outside the reference range that the investigator considers to be<br>             of clinical relevance<br><br>          -  Any evidence of a concomitant disease judged as clinically relevant by the<br>             investigator<br><br>          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,<br>             immunological or hormonal disorders<br><br>          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with<br>             the pharmacokinetics of the trial medication (except appendectomy and simple hernia<br>             repair)<br><br>          -  Diseases of the central nervous system (including but not limited to any kind of<br>             seizures or stroke), and other relevant neurological or psychiatric disorders<br><br>          -  History of relevant orthostatic hypotension, fainting spells, or blackouts<br><br>          -  Chronic or relevant acute infections<br><br>          -  History of relevant allergy or hypersensitivity (including allergy to the trial<br>             medication or its excipients)<br><br>          -  Use of drugs within 30 days prior to administration of trial medication that might<br>             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)<br><br>          -  Participation in another trial where an investigational drug has been administered<br>             within 60 days prior to planned administration of trial medication<br><br>          -  Current smoker or ex-smoker who quit smoking less than 30 days prior to screening<br><br>          -  Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for<br>             males)<br><br>          -  Drug abuse or positive drug screening<br><br>          -  Blood donation of more than 100 mL within 30 days prior to administration of trial<br>             medication or intended donation during the trial<br><br>          -  Intention to perform excessive physical activities within one week prior to<br>             administration of trial medication or during the trial<br><br>          -  Inability to comply with dietary regimen of trial site<br><br>          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are<br>             repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females)<br>             or any other relevant ECG finding at screening<br><br>          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,<br>             hypokalemia, or family history of Long QT Syndrome)<br><br>          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,<br>             because considered not able to understand and comply with study requirements, or has a<br>             condition that would not allow safe participation in the study<br><br>          -  History of major bleeding events (e.g. gastric bleeding, intracranial haemorrhage)<br>             based on the investigator's judgement<br><br>          -  Intake of drugs that may interfere with fluvoxamine such as monoamine oxidase<br>             inhibitors, and tizanidine.<br><br>          -  Intake of hormonal contraception or ovary hormone replacement therapy in female<br>             subjects<br><br>          -  Subjects with a medical history of suicidal behaviour<br><br>          -  History of increased intraocular pressure<br><br>          -  Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after<br>             study completion<br><br>          -  Lactation period<br>      ;<br>        Inclusion criteria:<br><br>          -  Healthy male or female subjects according to the investigator's assessment, based on a<br>             complete medical history including a physical examination, vital signs (BP, PR),<br>             12-lead ECG, and clinical laboratory tests<br><br>          -  Age of 18 to 50 years (incl.)<br><br>          -  BMI of 18.5 to 29.9 kg/m2 (incl.)<br><br>          -  Signed and dated written informed consent prior to admission to the study in<br>             accordance with GCP and local legislation<br><br>          -  Male or female subjects who meet any of the following criteria starting from screening<br>             until 30 days after trial completion regarding adequate contraception:<br><br>               -  Non-hormonal intra-uterine device in combination with condom<br><br>               -  Sexually abstinent<br><br>               -  Surgically sterilised (including hysterectomy)<br><br>               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)<br><br>               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in<br>                  questionable cases a blood sample with simultaneous levels of FSH above 40 U/L<br>                  and estradiol below 30 ng/L is confirmatory)<br><br>        Exclusion criteria:<br><br>          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from<br>             normal and judged as clinically relevant by the investigator<br><br>          -  Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,<br>             diastolic blood pressure outside the range of 60 to 90 mmHg, or pulse rate outside the<br>             range of 50 to 85 bpm<br><br>          -  Any laboratory value outside the reference range that the investigator considers to be<br>             of clinical relevance<br><br>          -  Any evidence of a concomitant disease judged as clinically relevant by the<br>             investigator<br><br>          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,<br>             immunological or hormonal disorders<br><br>          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with<br>             the pharmacokinetics of the trial medication (except appendectomy and simple hernia<br>             repair)<br><br>          -  Diseases of the central nervous system (including but not limited to any kind of<br>             seizures or stroke), and other relevant neurological or psychiatric disorders<br><br>          -  History of relevant orthostatic hypotension, fainting spells, or blackouts<br><br>          -  Chronic or relevant acute infections<br><br>          -  History of relevant allergy or hypersensitivity (including allergy to the trial<br>             medication or its excipients)<br><br>          -  Use of drugs within 30 days prior to administration of trial medication that might<br>             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)<br><br>          -  Participation in another trial where an investigational drug has been administered<br>             within 60 days prior to planned administration of trial medication<br><br>          -  Current smoker or ex-smoker who quit smoking less than 30 days prior to screening<br><br>          -  Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for<br>             males)<br><br>          -  Drug abuse or positive drug screening<br><br>          -  Blood donation of more than 100 mL within 30 days prior to administration of trial<br>             medication or intended donation during the trial<br><br>          -  Intention to perform excessive physical activities within one week prior to<br>             administration of trial medication or during the trial<br><br>          -  Inability to comply with dietary regimen of trial site<br><br>          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are<br>             repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females)<br>             or any other relevant ECG finding at screening<br><br>          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,<br>             hypokalemia, or family history of Long QT Syndrome)<br><br>          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,<br>             because considered not able to understand and comply with study requirements, or has a<br>             condition that would not allow safe participation in the study<br><br>          -  History of major bleeding events (e.g. gastric bleeding, intracranial haemorrhage)<br>             based on the investigator's judgement<br><br>          -  Intake of drugs that may interfere with fluvoxamine such as monoamine oxidase<br>             inhibitors, and tizanidine.<br><br>          -  Intake of hormonal contraception or ovary hormone replacement therapy in female<br>             subjects<br><br>          -  Subjects with a medical history of suicidal behaviour<br><br>          -  History of increased intraocular pressure<br><br>          -  Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after<br>             study completion<br><br>          -  Lactation period<br>      ;<br>        Inclusion criteria:<br><br>          -  Healthy male or female subjects according to the investigator's assessment, based on a<br>             complete medical history including a physical examination, vital signs (BP, PR),<br>             12-lead ECG, and clinical laboratory tests<br><br>          -  Age of 18 to 50 years (incl.)<br><br>          -  BMI of 18.5 to 29.9 kg/m2 (incl.)<br><br>          -  Signed and dated written informed consent prior to admission to the study in<br>             accordance with GCP and local legislation<br><br>          -  Male or female subjects who meet any of the following criteria starting from screening<br>             until 30 days after trial completion regarding adequate contraception:<br><br>               -  Non-hormonal intra-uterine device in combination with condom<br><br>               -  Sexually abstinent<br><br>               -  Surgically sterilised (including hysterectomy)<br><br>               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)<br><br>               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in<br>                  questionable cases a blood sample with simultaneous levels of FSH above 40 U/L<br>                  and estradiol below 30 ng/L is confirmatory)<br><br>        Exclusion criteria:<br><br>          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from<br>             normal and judged as clinically relevant by the investigator<br><br>          -  Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,<br>             diastolic blood pressure outside the range of 60 to 90 mmHg, or pulse rate outside the<br>             range of 50 to 85 bpm<br><br>          -  Any laboratory value outside the reference range that the investigator considers to be<br>             of clinical relevance<br><br>          -  Any evidence of a concomitant disease judged as clinically relevant by the<br>             investigator<br><br>          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,<br>             immunological or hormonal disorders<br><br>          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with<br>             the pharmacokinetics of the trial medication (except appendectomy and simple hernia<br>             repair)<br><br>          -  Diseases of the central nervous system (including but not limited to any kind of<br>             seizures or stroke), and other relevant neurological or psychiatric disorders<br><br>          -  History of relevant orthostatic hypotension, fainting spells, or blackouts<br><br>          -  Chronic or relevant acute infections<br><br>          -  History of relevant allergy or hypersensitivity (including allergy to the trial<br>             medication or its excipients)<br><br>          -  Use of drugs within 30 days prior to administration of trial medication that might<br>             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)<br><br>          -  Participation in another trial where an investigational drug has been administered<br>             within 60 days prior to planned administration of trial medication<br><br>          -  Current smoker or ex-smoker who quit smoking less than 30 days prior to screening<br><br>          -  Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for<br>             males)<br><br>          -  Drug abuse or positive drug screening<br><br>          -  Blood donation of more than 100 mL within 30 days prior to administration of trial<br>             medication or intended donation during the trial<br><br>          -  Intention to perform excessive physical activities within one week prior to<br>             administration of trial medication or during the trial<br><br>          -  Inability to comply with dietary regimen of trial site<br><br>          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are<br>             repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females)<br>             or any other relevant ECG finding at screening<br><br>          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,<br>             hypokalemia, or family history of Long QT Syndrome)<br><br>          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,<br>             because considered not able to understand and comply with study requirements, or has a<br>             condition that would not allow safe participation in the study<br><br>          -  History of major bleeding events (e.g. gastric bleeding, intracranial haemorrhage)<br>             based on the investigator's judgement<br><br>          -  Intake of drugs that may interfere with fluvoxamine such as monoamine oxidase<br>             inhibitors, and tizanidine.<br><br>          -  Intake of hormonal contraception or ovary hormone replacement therapy in female<br>             subjects<br><br>          -  Subjects with a medical history of suicidal behaviour<br><br>          -  History of increased intraocular pressure<br><br>          -  Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after<br>             study completion<br><br>          -  Lactation period<br>      ;<br>        Inclusion criteria:<br><br>          -  Healthy male or female subjects according to the investigator's assessment, based on a<br>             complete medical history including a physical examination, vital signs (BP, PR),<br>             12-lead ECG, and clinical laboratory tests<br><br>          -  Age of 18 to 50 years (incl.)<br><br>          -  BMI of 18.5 to 29.9 kg/m2 (incl.)<br><br>          -  Signed and dated written informed consent prior to admission to the study in<br>             accordance with GCP and local legislation<br><br>          -  Male or female subjects who meet any of the following criteria starting from screening<br>             until 30 days after trial completion regarding adequate contraception:<br><br>               -  Non-hormonal intra-uterine device in combination with condom<br><br>               -  Sexually abstinent<br><br>               -  Surgically sterilised (including hysterectomy)<br><br>               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)<br><br>               -  Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in<br>                  questionable cases a blood sample with simultaneous levels of FSH above 40 U/L<br>                  and estradiol below 30 ng/L is confirmatory)<br><br>        Exclusion criteria:<br><br>          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from<br>             normal and judged as clinically relevant by the investigator<br><br>          -  Repeated measurement of systolic blood pressure outside the range of 100 to 140 mmHg,<br>             diastolic blood pressure outside the range of 60 to 90 mmHg, or pulse rate outside the<br>             range of 50 to 85 bpm<br><br>          -  Any laboratory value outside the reference range that the investigator considers to be<br>             of clinical relevance<br><br>          -  Any evidence of a concomitant disease judged as clinically relevant by the<br>             investigator<br><br>          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,<br>             immunological or hormonal disorders<br><br>          -  Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with<br>             the pharmacokinetics of the trial medication (except appendectomy and simple hernia<br>             repair)<br><br>          -  Diseases of the central nervous system (including but not limited to any kind of<br>             seizures or stroke), and other relevant neurological or psychiatric disorders<br><br>          -  History of relevant orthostatic hypotension, fainting spells, or blackouts<br><br>          -  Chronic or relevant acute infections<br><br>          -  History of relevant allergy or hypersensitivity (including allergy to the trial<br>             medication or its excipients)<br><br>          -  Use of drugs within 30 days prior to administration of trial medication that might<br>             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)<br><br>          -  Participation in another trial where an investigational drug has been administered<br>             within 60 days prior to planned administration of trial medication<br><br>          -  Current smoker or ex-smoker who quit smoking less than 30 days prior to screening<br><br>          -  Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for<br>             males)<br><br>          -  Drug abuse or positive drug screening<br><br>          -  Blood donation of more than 100 mL within 30 days prior to administration of trial<br>             medication or intended donation during the trial<br><br>          -  Intention to perform excessive physical activities within one week prior to<br>             administration of trial medication or during the trial<br><br>          -  Inability to comply with dietary regimen of trial site<br><br>          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are<br>             repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females)<br>             or any other relevant ECG finding at screening<br><br>          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,<br>             hypokalemia, or family history of Long QT Syndrome)<br><br>          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,<br>             because considered not able to understand and comply with study requirements, or has a<br>             condition that would not allow safe participation in the study<br><br>          -  History of major bleeding events (e.g. gastric bleeding, intracranial haemorrhage)<br>             based on the investigator's judgement<br><br>          -  Intake of drugs that may interfere with fluvoxamine such as monoamine oxidase<br>             inhibitors, and tizanidine.<br><br>          -  Intake of hormonal contraception or ovary hormone replacement therapy in female<br>             subjects<br><br>          -  Subjects with a medical history of suicidal behaviour<br><br>          -  History of increased intraocular pressure<br><br>          -  Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after<br>             study completion<br><br>          -  Lactation period<br>